New Trial Designs to Assess Antitumor and Antiproliferative Agents in Prostate Cancer
- 1 May 2002
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 20 (2) , 201-208
- https://doi.org/10.1023/a:1015618108456
Abstract
The discovery of multiple putative therapeutic targets and multipleputative agents for these targets in prostate cancer in the coming yearsposes significant challenges for clinical trial design. This...Keywords
This publication has 23 references indexed in Scilit:
- CHARACTERIZATION AND PREDICTORS OF PROSTATE SPECIFIC ANTIGEN PROGRESSION RATES AFTER RADICAL RETROPUBIC PROSTATECTOMYJournal of Urology, 2000
- CHARACTERIZATION AND PREDICTORS OF PROSTATE SPECIFIC ANTIGEN PROGRESSION RATES AFTER RADICAL RETROPUBIC PROSTATECTOMYJournal of Urology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- TREATMENT OF EARLY RECURRENT PROSTATE CANCER WITH 1,25-DIHYDROXYVITAMIN D3 (CALCITRIOL)Journal of Urology, 1998
- Regulation of Growth, PSA/PAP and Androgen Receptor Expression by 1α,25-Dihydroxyvitamin D3in the Androgen-Dependent LNCaP CellsBiochemical and Biophysical Research Communications, 1996
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancerUrology, 1995
- Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and aids researchStatistics in Medicine, 1994
- Randomized discontinuation trials: Utility and efficiencyJournal of Clinical Epidemiology, 1993
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989